Foundry Partners LLC decreased its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 8.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 351,533 shares of the medical instruments supplier’s stock after selling 34,312 shares during the quarter. Foundry Partners LLC owned 0.95% of AngioDynamics worth $7,642,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of ANGO. Tributary Capital Management LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter valued at about $9,681,000. BlackRock Inc. increased its position in shares of AngioDynamics by 7.3% during the 2nd quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock valued at $121,848,000 after purchasing an additional 374,834 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of AngioDynamics during the 1st quarter valued at about $3,787,000. EAM Investors LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter valued at about $4,349,000. Finally, Acadian Asset Management LLC increased its position in shares of AngioDynamics by 226.1% during the 2nd quarter. Acadian Asset Management LLC now owns 260,789 shares of the medical instruments supplier’s stock valued at $5,798,000 after purchasing an additional 180,824 shares during the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.
ANGO has been the subject of several research reports. BidaskClub lowered shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 1st. Canaccord Genuity reaffirmed a “hold” rating and set a $20.00 price target on shares of AngioDynamics in a research report on Thursday, July 12th. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Finally, Raymond James lowered shares of AngioDynamics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 11th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AngioDynamics presently has a consensus rating of “Buy” and an average price target of $18.44.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, September 27th. The medical instruments supplier reported $0.16 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). The business had revenue of $85.34 million for the quarter, compared to analysts’ expectations of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. AngioDynamics’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.13 EPS. Sell-side analysts forecast that AngioDynamics, Inc. will post 0.85 EPS for the current fiscal year.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Further Reading: What is the Rule of 72?
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.